Advertisement

Frontiers of Medicine

, Volume 11, Issue 1, pp 87–96 | Cite as

Regulatory mechanism and functional analysis of S100A9 in acute promyelocytic leukemia cells

  • Yonglan Zhu
  • Fang Zhang
  • Shanzhen Zhang
  • Wanglong Deng
  • Huiyong Fan
  • Haiwei Wang
  • Ji Zhang
Research Article

Abstract

S100A9, a calcium-binding protein, participates in the inflammatory process and development of various tumors, thus attracting much attention in the field of cancer biology. This study aimed to investigate the regulatory mechanism of S100A9 and its function involvement in APL. We used real-time quantitative PCR to determine whether PML/RARα affects the expression of S100A9 in NB4 and PR9 cells upon ATRA treatment. ChIP-based PCR and dual-luciferase reporter assay system were used to detect how PML/RARα and PU.1 regulate S100A9 promoter activity. CCK-8 assay and flow cytometry were employed to observe the viability and apoptosis of NB4 cells when S100A9 was overexpressed. Results showed that S100A9 was an ATRA-responsive gene, and PML/RARα was necessary for the ATRA-induced expression of S100A9 in APL cells. In addition, PU.1 could bind to the promoter of S100A9, especially when treated with ATRA in NB4 cells, and promote its activity. More importantly, overexpression of S100A9 induced the apoptosis of NB4 cells and inhibited cell growth. Collectively, our data indicated that PML/RARα and PU.1 were necessary for the ATRA-induced expression of S100A9 in APL cells. Furthermore, S100A9 promoted apoptosis in APL cells and affected cell growth.

Keywords

S100A9 PU.1 PML/RARα ATRA APL 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Notes

Acknowledgements

This work was supported in part by the National Natural Science Foundation of China (No. 81370655), and the grants from Ministry of Science and Technology of China (Nos. 2013CB966802 and 2012AA02A505). We also greatly appreciated institutional supports from Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, China.

Supplementary material

11684_2016_469_MOESM1_ESM.pdf (173 kb)
Fig.S1 Arsenic trioxide had slight effect on the expression level of S100A9. The expression levels of S100A9 and PU.1 were detected at 24 h and 48 h treated with 1μmol/L arsenic trioxide in NB4 cells. GAPDH was used for normalization. The expression levels of S100A9 were examined at 24 h and 48 h treated with 1μmol/L ATRA or arsenic trioxide in NB4 cells. GAPDH was used for normalization. The data represent the mean of three replicates ± S.D.
11684_2016_469_MOESM2_ESM.xlsx (22 kb)
Supplementary material, approximately 22.1 KB.

References

  1. 1.
    de Thé H, Chen Z. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat Rev Cancer 2010; 10(11): 775–783CrossRefPubMedGoogle Scholar
  2. 2.
    Hu J, Liu YF, Wu CF, Xu F, Shen ZX, Zhu YM, Li JM, Tang W, Zhao WL, Wu W, Sun HP, Chen QS, Chen B, Zhou GB, Zelent A, Waxman S, Wang ZY, Chen SJ, Chen Z. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 2009; 106(9): 3342–3347CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Wang K, Wang P, Shi J, Zhu X, He M, Jia X, Yang X, Qiu F, Jin W, Qian M, Fang H, Mi J, Yang X, Xiao H, Minden M, Du Y, Chen Z, Zhang J. PML/RARα targets promoter regions containing PU.1 consensus and RARE half sites in acute promyelocytic leukemia. Cancer Cell 2010; 17(2): 186–197CrossRefPubMedGoogle Scholar
  4. 4.
    Wei S, Zhao M, Wang X, Li Y, Wang K. PU.1 controls the expression of long noncoding RNA HOTAIRM1 during granulocytic differentiation. J Hematol Oncol 2016; 9(1): 44CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Qian M, Jin W, Zhu X, Jia X, Yang X, Du Y, Wang K, Zhang J. Structurally differentiated cis-elements that interact with PU.1 are functionally distinguishable in acute promyelocytic leukemia. J Hematol Oncol 2013; 6(1): 25CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Donato R. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol 2001; 33(7): 637–668CrossRefPubMedGoogle Scholar
  7. 7.
    Nacken W, Roth J, Sorg C, Kerkhoff C. S100A9/S100A8: myeloid representatives of the S100 protein family as prominent players in innate immunity. Microsc Res Tech 2003; 60(6): 569–580CrossRefPubMedGoogle Scholar
  8. 8.
    Hunter MJ, Chazin WJ. High level expression and dimer characterization of the S100 EF-hand proteins, migration inhibitory factor-related proteins 8 and 14. J Biol Chem 1998; 273(20): 12427–12435CrossRefPubMedGoogle Scholar
  9. 9.
    Srikrishna G. S100A8 and S100A9: new insights into their roles in malignancy. J Innate Immun 2012; 4(1): 31–40CrossRefPubMedGoogle Scholar
  10. 10.
    Salama I, Malone PS, Mihaimeed F, Jones JL. A review of the S100 proteins in cancer. Eur J Surg Oncol 2008; 34(4): 357–364CrossRefPubMedGoogle Scholar
  11. 11.
    Khammanivong A, Wang C, Sorenson BS, Ross KF, Herzberg MC. S100A8/A9 (calprotectin) negatively regulates G2/M cell cycle progression and growth of squamous cell carcinoma. PLoS ONE 2013; 8(7): e69395CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Yui S, Nakatani Y, Mikami M. Calprotectin (S100A8/S100A9), an inflammatory protein complex from neutrophils with a broad apoptosis-inducing activity. Biol Pharm Bull 2003; 26(6): 753–760CrossRefPubMedGoogle Scholar
  13. 13.
    Kuwayama A, Kuruto R, Horie N, Takeishi K, Nozawa R. Appearance of nuclear factors that interact with genes for myeloid calcium binding proteins (MRP-8 and MRP-14) in differentiated HL-60 cells. Blood 1993; 81(11): 3116–3121PubMedGoogle Scholar
  14. 14.
    Tomasson MH, Xiang Z, Walgren R, Zhao Y, Kasai Y, Miner T, Ries RE, Lubman O, Fremont DH, McLellan MD, Payton JE, Westervelt P, DiPersio JF, Link DC, Walter MJ, Graubert TA, Watson M, Baty J, Heath S, Shannon WD, Nagarajan R, Bloomfield CD, Mardis ER, Wilson RK, Ley TJ. Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. Blood 2008; 111(9): 4797–4808CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Grignani F, Ferrucci PF, Testa U, Talamo G, Fagioli M, Alcalay M, Mencarelli A, Grignani F, Peschle C, Nicoletti I, Pelicci PG. The acute promyelocytic leukemia-specific PML-RAR α fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell 1993; 74(3): 423–431CrossRefPubMedGoogle Scholar
  16. 16.
    Bealer JF, Colgin M. S100A8/A9: a potential new diagnostic aid for acute appendicitis. Acad Emerg Med 2010; 17(3): 333–336CrossRefPubMedGoogle Scholar
  17. 17.
    Horvath I, Jia X, Johansson P, Wang C, Moskalenko R, Steinau A, Forsgren L, Wågberg T, Svensson J, Zetterberg H, Morozova-Roche LA. Pro-inflammatory S100A9 protein as a robust biomarker differentiating early stages of cognitive impairment in Alzheimer’s disease. ACS Chem Neurosci 2016; 7(1): 34–39CrossRefPubMedGoogle Scholar
  18. 18.
    van Bon L, Cossu M, Loof A, Gohar F, Wittkowski H, Vonk M, Roth J, van den Berg W, van Heerde W, Broen JC, Radstake TR. Proteomic analysis of plasma identifies the Toll-like receptor agonists S100A8/A9 as a novel possible marker for systemic sclerosis phenotype. Ann Rheum Dis 2014; 73(8): 1585–1589CrossRefPubMedGoogle Scholar
  19. 19.
    Kim WT, Kim J, Yan C, Jeong P, Choi SY, Lee OJ, Chae YB, Yun SJ, Lee SC, Kim WJ. S100A9 and EGFR gene signatures predict disease progression in muscle invasive bladder cancer patients after chemotherapy. Ann Oncol 2014; 25(5): 974–979CrossRefPubMedGoogle Scholar
  20. 20.
    Li Z, Luo RT, Mi S, Sun M, Chen P, Bao J, Neilly MB, Jayathilaka N, Johnson DS, Wang L, Lavau C, Zhang Y, Tseng C, Zhang X, Wang J, Yu J, Yang H, Wang SM, Rowley JD, Chen J, Thirman MJ. Consistent deregulation of gene expression between human and murine MLL rearrangement leukemias. Cancer Res 2009; 69(3): 1109–1116CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Ishii Y, Kasukabe T, Honma Y. Immediate up-regulation of the calcium-binding protein S100P and its involvement in the cytokinin-induced differentiation of human myeloid leukemia cells. Biochim Biophys Acta 2005; 1745(2): 156–165CrossRefPubMedGoogle Scholar
  22. 22.
    Roth J, Goebeler M, van den Bos C, Sorg C. Expression of calcium-binding proteins MRP8 and MRP14 is associated with distinct monocytic differentiation pathways in HL-60 cells. Biochem Biophys Res Commun 1993; 191(2): 565–570CrossRefPubMedGoogle Scholar
  23. 23.
    Wang JG, Barsky LW, Davicioni E, Weinberg KI, Triche TJ, Zhang XK, Wu L. Retinoic acid induces leukemia cell G1 arrest and transition into differentiation by inhibiting cyclin-dependent kinaseactivating kinase binding and phosphorylation of PML/RARα. FASEB J 2006; 20(12): 2142–2144CrossRefPubMedGoogle Scholar
  24. 24.
    Nervi C, Ferrara FF, Fanelli M, Rippo MR, Tomassini B, Ferrucci PF, Ruthardt M, Gelmetti V, Gambacorti-Passerini C, Diverio D, Grignani F, Pelicci PG, Testi R. Caspases mediate retinoic acidinduced degradation of the acute promyelocytic leukemia PML/RARα fusion protein. Blood 1998; 92(7): 2244–2251PubMedGoogle Scholar
  25. 25.
    Grignani F, Gelmetti V, Fanelli M, Rogaia D, De Matteis S, Ferrara FF, Bonci D, Grignani F, Nervi C, Pelicci PG. Formation of PML/RAR alpha high molecular weight nuclear complexes through the PML coiled-coil region is essential for the PML/RARα-mediated retinoic acid response. Oncogene 1999; 18(46): 6313–6321CrossRefPubMedGoogle Scholar
  26. 26.
    Kim JH, Oh SH, Kim EJ, Park SJ, Hong SP, Cheon JH, Kim TI, Kim WH. The role of myofibroblasts in upregulation of S100A8 and S100A9 and the differentiation of myeloid cells in the colorectal cancer microenvironment. Biochem Biophys Res Commun 2012; 423(1): 60–66CrossRefPubMedGoogle Scholar
  27. 27.
    Bando M, Zou X, Hiroshima Y, Kataoka M, Ross KF, Shinohara Y, Nagata T, Herzberg MC, Kido J. Mechanism of interleukin-1α transcriptional regulation of S100A9 in a human epidermal keratinocyte cell line. Biochim Biophys Acta 2013; 1829(9): 954–962CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Li C, Chen H, Ding F, Zhang Y, Luo A, Wang M, Liu Z. A novel p53 target gene, S100A9, induces p53-dependent cellular apoptosis and mediates the p53 apoptosis pathway. Biochem J 2009; 422(2): 363–372CrossRefPubMedGoogle Scholar
  29. 29.
    McKercher SR, Torbett BE, Anderson KL, Henkel GW, Vestal DJ, Baribault H, Klemsz M, Feeney AJ, Wu GE, Paige CJ, Maki RA. Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities. EMBO J 1996; 15(20): 5647–5658PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Chau D, Ng K, Chan TSY, Cheng YY, Fong B, Tam S, Kwong YL, Tse E. Azacytidine sensitizes acute myeloid leukemia cells to arsenic trioxide by up-regulating the arsenic transporter aquaglyceroporin 9. J Hematol Oncol 2015; 8(1): 46CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Zhang Y, Zhang Z, Li J, Li L, Han X, Han L, Hu L, Wang S, Zhao Y, Li X, Zhang Y, Fan S, Lv C, Li Y, Su Y, Zhao H, Zhang X, Zhou J. Long-term efficacy and safety of arsenic trioxide for first-line treatment of elderly patients with newly diagnosed acute promyelocytic leukemia. Cancer 2013; 119(1): 115–125CrossRefPubMedGoogle Scholar
  32. 32.
    Shen ZX, Shi ZZ, Fang J, Gu BW, Li JM, Zhu YM, Shi JY, Zheng PZ, Yan H, Liu YF, Chen Y, Shen Y, Wu W, Tang W, Waxman S, De Thé H, Wang ZY, Chen SJ, Chen Z. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 2004; 101(15): 5328–5335CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Higher Education Press and Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Yonglan Zhu
    • 1
  • Fang Zhang
    • 1
  • Shanzhen Zhang
    • 2
  • Wanglong Deng
    • 1
  • Huiyong Fan
    • 1
  • Haiwei Wang
    • 1
    • 2
  • Ji Zhang
    • 1
    • 2
  1. 1.State Key Laboratory of Medical GenomicsRuijin Hospital Affiliated to Shanghai Jiao Tong University School of MedicineShanghaiChina
  2. 2.Medical Institute of Health SciencesChinese Academy of SciencesShanghaiChina

Personalised recommendations